Phase I trial results for ZP4207 support its further development as a rescue treatment for severe hypoglycaemia
Zealand has announced results from a clinical Phase I trial…
Zealand has announced results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207.